Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients.
Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, full-dose anticoagulation drugs did not improve outcomes. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.
As is normal for clinical trials, these trials are overseen by independent boards that routinely review the data and are composed of experts in ethics, biostatistics, clinical trials, and blood clotting disorders. Informed by the deliberations of these oversight boards, all of the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19.
The potential for harm in this sub-group could not be excluded. Increased bleeding is a known complication of full-dose anticoagulation. The trials are working urgently to undertake additional analyses which will be made available as soon as possible.
At the recommendation of the oversight boards patients who do not require ICU care at the time of enrollment will continue to be enrolled in the trial. Whether the use of full-dose compared to low-dose blood thinners leads to better outcomes in hospitalized patients with less severe disease remains a very important question.
COVID-19 is associated with significant inflammation and clinical and pathologic evidence of widespread blood clots. These trials were launched because clinicians have observed that many patients ill with COVID-19, including those who have died from the disease, formed blood clots throughout their bodies, even in their smallest blood vessels.
This unusual clotting can cause multiple health complications, including lung failure, heart attack, and stroke.
"In only our most critically ill patients with COVID-19, all of our trial sites have paused enrollment while we further analyze the data. These results question the benefit of giving full-dose anticoagulants routinely in COVID-19 patients who are admitted to an ICU," said Ryan Zarychanski, M.D., M.Sc., Israels associate professor of medicine at the University of Manitoba and CancerCare Manitoba in Canada, a hematologist and critical care physician, who led the harmonization of the three trials.
The multiple platform randomized controlled trial (mpRCT) represents an unprecedented collaboration between three international partners.
The Randomized, Embedded, Multi-factorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) Therapeutic Anticoagulation; Accelerating COVID-19 Therapeutic Interventions and Vaccines-4 (ACTIV-4) Antithrombotics Inpatient; and Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) are a set of clinical trial platforms spanning five continents with the common goal of testing whether there is a benefit of full doses of blood thinners to treat adults hospitalized for COVID-19 illness on the ward or in the ICU compared to the lower dose used to prevent blood clots in hospitalized patients.
To meet the challenge of this pandemic, investigators worldwide joined forces to answer this question as rapidly as possible.
These results represent an immense collaborative effort involving patients, clinicians, and research staff around the world enabling us to rapidly learn how best to treat Covid-19. The strength of the multiplatform clinical trial design enables us to pause in one subset and continue parts of the study."
Ewan Goligher, MD, PhD, Assistant Professor, University of Toronto, Scientist, Toronto General Hospital Research Institute, University Health Network, Critical Care Physician
Link between COVID-19 and long-term risk of autoimmune and autoinflammatory connective tissue disorders